Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)

Citation
Pj. Hollen et al., Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS), SUPP CARE C, 7(3), 1999, pp. 140-148
Citations number
23
Categorie Soggetti
Health Care Sciences & Services
Journal title
SUPPORTIVE CARE IN CANCER
ISSN journal
09414355 → ACNP
Volume
7
Issue
3
Year of publication
1999
Pages
140 - 148
Database
ISI
SICI code
0941-4355(199905)7:3<140:NDATIQ>2.0.ZU;2-E
Abstract
Normative data and trends for a disease- and site-specific quality of life (QL) instrument for individuals with lung cancel; the Lung Cancer Symptom S cale (LCSS), are presented to facilitate the user's interpretation of test scores. Data for patients enrolled in two large, identical, randomized tria ls of a new combination chemotherapy regimen for patients with stages III a nd IV non-small-cell lung cancer (NSCLC) were combined into one dataset (n= 673). For these patients with a Karnofsky performance status (KPS) of 60-10 0%, QL had been prospectively measured at baseline, day 29 and every 6 week s thereafter. Descriptive statistics for the LCSS are presented for three t ime points (baseline, day 29 and day 71) and for specific demographic and d isease-related characteristics (age, gender, race, performance status and s tage of disease) to provide expected values and their variability during ch emotherapy. Data from a small dataset of 63 NSCLC inpatients with KPS score s of 20-50% are also presented for a comparison sample of supportive care f or inpatients and hospice patients. For the 673 NSCLC patients at baseline there were no significant differences in QL by age, gen-der, or race. Major presenting lung cancer symptoms at baseline for this combined sample were dyspnea 87%, cough 86% pain 81%, loss of appetite 75%, and hemoptysis 41%. Of these patients, 81% had three or more presenting symptoms at baseline (2 % had no symptoms; 5%, one symptom; 12% two symptoms; 18%, three symptoms; 27%, four symptoms; and 36%, five symptoms). The mean LCSS baseline score ( best = 0; worst = 100) was 26.56 (SD 16.10). The mean scores for day 29 and day 71 were 25.46 (SD 16.52) and 25.30 (SD 16.93), respectively, but follo w-up assessments on progressers were not obtained. Stage III patients had a mean LCSS score of 23.7 (SD 15.1), whereas stage IV patients reported a me an LCSS score of 27.3 (SD 16.3). The mean LCSS score for the group with KPS 60-70% was 34.8 (SD 15.5), and that for the group with KPS 80-100% was 23. 3 (SD 15.1). The mean LCSS score for the lower performance group, with KPS scores of 20-50% at baseline, was 46.85 (SD 17.65).